Valuation dashboard for BioAtla, Inc. (BCAB) with P/E N/A, P/B -0.08, EV/EBITDA -0.25 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated for its potential against soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC), and ovarian cancer.
Analysis Summary
BioAtla, Inc. reported revenue of $2.0M in the most recent fiscal year, growing at a 5-year CAGR of 36.1%.
Trailing-twelve-month margins: gross margin -4.2%, operating margin -372.1%, net margin -370.0%.
At the current price of $1.74, BCAB has negative trailing earnings (P/E not meaningful) and an ROE of 89.25%. Market capitalisation stands at $3M.
Balance sheet quality for BCAB: current ratio of 0.4. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | -0.08 |
| EV / EBITDA | -0.25 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-4.95 |
| vs Current Price | -385.3% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| BCAB | BioAtla, Inc. | $3M | 89.2% | ||
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $1.74 |
| Market Cap | $3M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | 89.25% |
| Return on Invested Capital | 318.00% |
| Return on Assets | -330.89% |
| Gross Margin | -4.15% |
| Operating Margin | -372.06% |
| Net Margin | -370.05% |
Related companies: ANVS · BTAI · CELU · EVAX · GBIO · MRSN · MURA
Explore sector: Healthcare · Biotechnology
More sections of BCAB: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks